Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Bortezomib Dexamethasone and High-dose Melphalan in Patients With Relapse After High-dose Melphalan With Autologous Stem Cell Support

NCT00508209 is registered in ClinicalTrials.gov with Nordic Myeloma Study Group as lead sponsor.

NCT NCT00508209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00508209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Bortezomib Dexamethasone and High-dose Melphalan in Patients With Relapse After High-dose Melphalan With Autologous Stem Cell Support
Lead sponsor
Nordic Myeloma Study Group
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2007
Completion date
September 30, 2010
Enrollment
50 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma